IRRAS announced that the publication of the first comparative study detailing the use of the company's novel IRRAflow system. This study, which was conducted under the guidance of Dr. Adnan Siddiqui and the team from the Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, one of the world's leading centers for neurosurgical innovation, was published in the peer-reviewed Operative Neurosurgery medical journal. The manuscript concludes that IRRAS' IRRAflow system when used for the treatment of chronic subdural hematomas (cSDH) results in favorable clinical outcomes, low complication and revision rates, faster clearance of collected blood, and reduced rates of catheter infections compared to passive drainage using an external ventricular drain (EVD).

After the completion of the analysis, the surgeons found that the use of IRRAflow resulted in a statistically significant higher rate of hematoma clearance (0.5 ± 0.4 mL/day with IRRAflow vs. 0.4 ± 0.5 mL/day with passive drainage) and a statistically significant reduction in catheter-related infections. Additionally, in the subgroup analysis that looked procedures that were performed using a burrhole alone, treatment with IRRAflow also resulted in significantly lower hematoma expansion at discharge and significantly improved brain expansion.

Furthermore, the data from this clinical study showed that the use of IRRAflow resulted in a nonsignificant reduction in duration of catheter placement (3.7 ± 2.2 with IRRAflow vs. 4.4 ± 4.1 with passive drainage), total hospital length of stay (6.8 ± 3.0 with IRRAflow vs. 10.6 ± 16.2 with passive drainage), and rate of seizure activity (0 patients with IRRAflow vs.

3 patients with passive drainage), each suggesting a trend that may have shown significance with a larger sample size.